Publication: A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
Date
Date
Date
Citations
Soo, R. A., Vervita, K., Früh, M., Cho, B. C., Majem, M., Rodriguez Abreu, D., Ribi, K., Callejo, A., Moran, T., Domine Gomez, M., Provencio, M., Addeo, A., Han, J. Y., Ortega Granados, A. L., Reck, M., Blasco, A., Garcia Campelo, R., Sala González, M. A., Britschgi, C., … ETOP 15-19 ABC-lung collaborators. (2025). A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer, 202, 108454. https://doi.org/10.1016/j.lungcan.2025.108454
Abstract
Abstract
Abstract
ABC-lung explores the potential effect of combining atezolizumab and bevacizumab with either carboplatin/paclitaxel (ABCPac) or pemetrexed (ABPem) in patients with EGFR-mutant NSCLC, resistant to tyrosine kinase inhibitors (TKIs). ABC-lung is a 1:1 randomised, non-comparative, phase II trial, stratified by prior treatment with a third-generation EGFR TKI, evaluating atezolizumab (1200 mg, Q3W) and bevacizumab (15mg/kg, Q3W) with either 4-6 cycles of carboplatin (AUC5, Q3W) and paclitaxel (175-200mg/m2, Q3W) or pemetrexed (500 mg/m2, Q
Metrics
Views
Citations
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
Publisher
Publisher
Publisher
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Views
Citations
Citations
Soo, R. A., Vervita, K., Früh, M., Cho, B. C., Majem, M., Rodriguez Abreu, D., Ribi, K., Callejo, A., Moran, T., Domine Gomez, M., Provencio, M., Addeo, A., Han, J. Y., Ortega Granados, A. L., Reck, M., Blasco, A., Garcia Campelo, R., Sala González, M. A., Britschgi, C., … ETOP 15-19 ABC-lung collaborators. (2025). A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer, 202, 108454. https://doi.org/10.1016/j.lungcan.2025.108454
